Selected angle: source

One-sentence thesis

The cited A/B receipts support a specific working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

Real tension: the surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; adults with overweight or obesity with at least one weight-related comorbidity, without diabetes. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

Evidence Landscape

Bounded research question: Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

Evidence receipts

• fact_id=161900 (A_core) — Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%) source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit
• fact_id=158054 (A_core) — Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo source=Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or O
• fact_id=100298 (A_core) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) doi=10.1111/obr.13792
• fact_id=145390 (A_core) — Gastrointestinal adverse events were reported more often with semaglutide than with placebo (82.2% versus 53.9%). doi=10.1038/s41591-022-02026-4
• fact_id=149514 (A_core) — semaglutide (1.8%) versus placebo (2.2%) doi=10.1038/s41591-024-03015-5

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=100298 (A_core) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) Source: Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—
• fact_id=136841 (A_core) — MACE-4 events tended to be reduced, with no hazard ratio > 1.0 and upper CI bounds < 1.3 Source: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic cont
• fact_id=137771 (A_core) — semaglutide 2.4 mg was associated with mean weight losses of 14.9%-17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68 Source: Semaglutide for the treatment of overweight and obesity: A review

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.